|
Nolan: A randomized, phase II study to estimate the effect of prophylactic naproxen (N) or loratadine (L) vs no intervention on bone pain in 600 patients (pts) with early-stage breast cancer receiving chemotherapy (chemo) and pegfilgrastim (PEG). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Trevena |
Speakers' Bureau - The Medicine Shoppe Pharmacy |
|
|
Employment - Miami Cancer Institute; Tesaro |
Leadership - Miami Cancer Institute; Tesaro |
Stock and Other Ownership Interests - Tesaro |
Honoraria - Amgen; Genentech; Novartis |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Amgen; Genentech; Novartis |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |